7/15 N/A
et al., Med. Hypotheses, doi:10.1016/j.mehy.2020.110110 (Peer Reviewed)
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
Proposal to use an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma. Authors advocate for early treatment or prophylaxis of COVID-19, using HCQ as an inhaled aerosol, to deliver the drug directly to the lungs at a lower dose than that required for oral systemic delivery.
Kavanagh et al., 7/15/2020, peer-reviewed, 9 authors.
